• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

从卫生行政数据中识别阿片类激动剂治疗处方医生网络:一项验证研究。

Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study.

作者信息

Kurz Megan, Tatangelo Mark, Morin Kristen A, Zanette Michelle, Krebs Emanuel, Marsh David C, Nosyk Bohdan

机构信息

Centre for Advancing Health Outcomes, Vancouver, BC, Canada.

Faculty of Health Sciences, Simon Fraser University, Burnaby, BC, Canada.

出版信息

PLoS One. 2025 May 16;20(5):e0322064. doi: 10.1371/journal.pone.0322064. eCollection 2025.

DOI:10.1371/journal.pone.0322064
PMID:40378100
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12083784/
Abstract

BACKGROUND

Given the growth of collaborative care strategies for people with opioid use disorder and the changing composition of the illicit drug supply, there is a need to identify and analyze clinic-level outcomes for centers prescribing opioid agonist treatment (OAT). We aimed to determine and validate whether prescriber networks, constructed with administrative data, can successfully identify distinct clinical practice facilities in Ontario, Canada.

METHODS

We executed a retrospective population-based cohort study using OAT prescription records from the Canadian Addiction Treatment Centres in Ontario, Canada between 01/01/2013 and 12/31/2020. Social network analysis was utilized to create networks with connections between physicians based on their shared OAT clients. We defined connections two different ways, by including the number of clients shared or a relative threshold on the percentage of shared OAT clients per physician. Clinics were identified using modularity maximization, with sensitivity analyses applying Louvain, Walktrap, and Label Propagation algorithms. Concordance between network-identified facilities and the (gold standard) de-identified facility-level IDs was assessed using overall, positive and negative agreement, sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV).

RESULTS

From 144 physicians at 105 clinics with 32,842 OAT clients, we assessed 250 different versions of the created networks. The three different detection algorithms had wide variation in concordance, with ranges on sensitivity from 0.02 to 0.88 and PPV from 0.06 to 0.97. The optimal result, derived from the modularity maximization method, achieved high specificity (0.98, 95% CI: 0.98, 0.98) and NPV (0.98, 95% CI: 0.97, 0.98) and moderate PPV (0.54, 95% CI: 0.52, 0.57) and sensitivity (0.45, 95% CI: 0.43, 0.47). This scenario had an overall agreement of 0.96, negative agreement of 0.98, and positive agreement of 0.49.

CONCLUSIONS

Social network analysis can be used to identify clinics prescribing OAT in the absence of clinic-level identifiers, thus facilitating construction and comparison of clinic-level caseloads and treatment outcomes.

摘要

背景

鉴于阿片类药物使用障碍患者的协作护理策略不断发展以及非法药物供应构成的变化,有必要识别和分析开具阿片类激动剂治疗(OAT)的中心在临床层面的结果。我们旨在确定并验证利用行政数据构建的处方医生网络能否成功识别加拿大安大略省不同的临床实践机构。

方法

我们进行了一项基于人群的回顾性队列研究,使用了2013年1月1日至2020年12月31日期间加拿大安大略省成瘾治疗中心的OAT处方记录。利用社会网络分析,根据医生共享的OAT患者创建医生之间有联系的网络。我们通过两种不同方式定义联系,一种是纳入共享患者数量,另一种是设定每位医生共享OAT患者百分比的相对阈值。使用模块度最大化方法识别诊所,并运用Louvain、Walktrap和标签传播算法进行敏感性分析。使用总体一致性、阳性一致性和阴性一致性、敏感性、特异性、阳性预测值(PPV)和阴性预测值(NPV)评估网络识别的机构与(黄金标准)去识别化的机构层面ID之间的一致性。

结果

在105家诊所的144名医生及32,842名OAT患者中,我们评估了创建网络的250个不同版本。三种不同的检测算法在一致性方面差异很大,敏感性范围为0.02至0.88,PPV范围为0.06至0.97。通过模块度最大化方法得出的最佳结果具有高特异性(0.98,95%CI:0.98,0.98)和NPV(0.98,95%CI:0.97,0.98)以及中等的PPV(0.54,95%CI:0.52,0.57)和敏感性(0.45,95%CI:0.43,0.47)。这种情况下总体一致性为0.96,阴性一致性为0.98,阳性一致性为0.49。

结论

在没有诊所层面标识符的情况下,社会网络分析可用于识别开具OAT的诊所,从而便于构建和比较诊所层面的病例负荷及治疗结果。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0604/12083784/2c4f584a17c1/pone.0322064.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0604/12083784/2c47de110d75/pone.0322064.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0604/12083784/2c4f584a17c1/pone.0322064.g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0604/12083784/2c47de110d75/pone.0322064.g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0604/12083784/2c4f584a17c1/pone.0322064.g002.jpg

相似文献

1
Identifying opioid agonist treatment prescriber networks from health administrative data: A validation study.从卫生行政数据中识别阿片类激动剂治疗处方医生网络:一项验证研究。
PLoS One. 2025 May 16;20(5):e0322064. doi: 10.1371/journal.pone.0322064. eCollection 2025.
2
Prescription of Controlled Substances: Benefits and Risks管制药品的处方:益处与风险
3
Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.加拿大安大略省加拿大成瘾治疗中心(CATC)阿片类激动剂治疗队列。
BMJ Open. 2024 Feb 24;14(2):e080790. doi: 10.1136/bmjopen-2023-080790.
4
Measuring treatment attrition at various stages of engagement in Opioid Agonist Treatment in Ontario Canada using a cascade of care framework.使用关怀传递框架衡量加拿大安大略省阿片类激动剂治疗各个阶段的治疗脱落情况。
BMC Health Serv Res. 2022 Apr 12;22(1):490. doi: 10.1186/s12913-022-07877-8.
5
Inequities in access to primary care among opioid recipients in Ontario, Canada: A population-based cohort study.加拿大安大略省阿片类药物使用者获得初级保健服务的不平等:基于人群的队列研究。
PLoS Med. 2021 Jun 1;18(6):e1003631. doi: 10.1371/journal.pmed.1003631. eCollection 2021 Jun.
6
Patterns of physician prescribing for opioid maintenance treatment in Ontario, Canada in 2014.2014年加拿大安大略省阿片类药物维持治疗的医生处方模式。
Drug Alcohol Depend. 2017 Aug 1;177:315-321. doi: 10.1016/j.drugalcdep.2017.05.002. Epub 2017 Jul 19.
7
Prescribing practices in opioid agonist treatment and changes in compliance to clinical dosing guidelines in British Columbia, Canada.在加拿大不列颠哥伦比亚省,阿片类激动剂治疗中的处方实践和对临床剂量指南的遵从性变化。
Addiction. 2024 Aug;119(8):1453-1459. doi: 10.1111/add.16491. Epub 2024 Apr 7.
8
Cohort profile: the provincial opioid agonist treatment cohort in Ontario, Canada.队列简介:加拿大安大略省省级阿片类激动剂治疗队列
Eur J Epidemiol. 2025 Feb;40(2):235-243. doi: 10.1007/s10654-025-01202-3. Epub 2025 Jan 27.
9
Inability to contact opioid agonist therapy prescribers during the COVID-19 pandemic in a Canadian setting: a cross-sectional analysis among people on opioid agonist therapy.在加拿大,COVID-19 大流行期间无法联系阿片类激动剂治疗医生:阿片类激动剂治疗者中的横断面分析。
Addict Sci Clin Pract. 2022 Dec 15;17(1):73. doi: 10.1186/s13722-022-00354-x.
10
Opioid agonist treatment (OAT) experiences and release plans among federally incarcerated individuals with opioid use disorder (OUD) in Ontario, Canada: a mixed-methods study.加拿大安大略省患有阿片类药物使用障碍(OUD)的联邦监狱服刑人员的阿片类激动剂治疗(OAT)经历与释放计划:一项混合方法研究
BMC Public Health. 2022 Mar 4;22(1):436. doi: 10.1186/s12889-022-12685-0.

本文引用的文献

1
Canadian Addiction Treatment Centre (CATC) opioid agonist treatment cohort in Ontario, Canada.加拿大安大略省加拿大成瘾治疗中心(CATC)阿片类激动剂治疗队列。
BMJ Open. 2024 Feb 24;14(2):e080790. doi: 10.1136/bmjopen-2023-080790.
2
Comparative Analysis of Instrumental Variables on the Assignment of Buprenorphine/Naloxone or Methadone for the Treatment of Opioid Use Disorder.比较工具变量在丁丙诺啡/纳洛酮或美沙酮治疗阿片类药物使用障碍中的分配效果。
Epidemiology. 2024 Mar 1;35(2):218-231. doi: 10.1097/EDE.0000000000001697. Epub 2023 Jan 30.
3
Influence of physician networks on the implementation of pharmaceutical alternatives to a toxic drug supply in British Columbia.
医师网络对不列颠哥伦比亚省有毒药品供应替代药品实施的影响。
Implement Sci. 2024 Jan 6;19(1):3. doi: 10.1186/s13012-023-01331-x.
4
Rapid Access Addiction Medicine Clinics for People With Problematic Opioid Use.快速通道成瘾医学诊所,为有问题阿片类药物使用的人群提供服务。
JAMA Netw Open. 2023 Nov 1;6(11):e2344528. doi: 10.1001/jamanetworkopen.2023.44528.
5
Responding to the opioid crisis in North America and beyond: recommendations of the Stanford-Lancet Commission.应对北美及其他地区的阿片类药物危机:斯坦福-柳叶刀委员会的建议
Lancet. 2022 Feb 5;399(10324):555-604. doi: 10.1016/S0140-6736(21)02252-2. Epub 2022 Feb 2.
6
Assessing the determinants of completing OAT induction and long-term retention: A population-based study in British Columbia, Canada.评估完成 OAT 诱导和长期保留的决定因素:加拿大不列颠哥伦比亚省的一项基于人群的研究。
J Subst Abuse Treat. 2022 Feb;133:108647. doi: 10.1016/j.jsat.2021.108647. Epub 2021 Oct 26.
7
Influence of physician networks on prescribing a new ingredient combination in heart failure: a longitudinal claim data-based study.医生网络对心力衰竭新配方药物处方的影响:一项基于纵向索赔数据的研究。
Implement Sci. 2021 Aug 28;16(1):84. doi: 10.1186/s13012-021-01150-y.
8
Preference-based instrumental variables in health research rely on important and underreported assumptions: a systematic review.健康研究中基于偏好的工具变量依赖于重要但报告不足的假设:系统评价。
J Clin Epidemiol. 2021 Nov;139:269-278. doi: 10.1016/j.jclinepi.2021.06.006. Epub 2021 Jun 11.
9
Retention of opioid agonist treatment prescribers across New South Wales, Australia, 2001-2018: Implications for treatment systems and potential impact on client outcomes.澳大利亚新南威尔士州 2001-2018 年阿片类激动剂治疗处方医生保留情况:对治疗系统的影响及对患者结局的潜在影响。
Drug Alcohol Depend. 2021 Feb 1;219:108464. doi: 10.1016/j.drugalcdep.2020.108464. Epub 2020 Dec 19.
10
How to Identify Team-based Primary Care in the United States Using Medicare Data.如何利用医疗保险数据识别美国的团队式初级保健。
Med Care. 2021 Feb 1;59(2):118-122. doi: 10.1097/MLR.0000000000001478.